What's Happening?
A recent perspective article in the Journal of Human Hypertension discusses the potential of long-acting RNA interference (RNAi) therapies, such as zilebesiran, to transform hypertension care. These therapies can suppress blood pressure for months with
a single dose, shifting the burden of care from patients to healthcare systems. However, the article warns of a 'pharmacological moral hazard,' where patients might neglect necessary lifestyle changes due to a false sense of security provided by the medication. The article emphasizes the need for structured healthcare checkpoints to ensure ongoing cardiovascular risk management and lifestyle advice.
Why It's Important?
The introduction of long-acting RNAi therapies like zilebesiran could significantly impact hypertension management by improving medication adherence and reducing the daily burden on patients. This shift could democratize cardiovascular protection, potentially reducing the global burden of hypertension, a leading cause of death and disability. However, the success of this approach depends on healthcare systems effectively managing patient follow-up and lifestyle counseling. The potential for patients to deprioritize lifestyle changes poses a risk to holistic cardiovascular health, highlighting the need for comprehensive care models.
What's Next?
The upcoming ZENITH trial, involving approximately 11,000 patients, will further evaluate the efficacy of twice-yearly angiotensinogen silencing in reducing cardiovascular events. The trial's outcomes could influence future hypertension policies and the integration of RNAi therapies into standard care. Healthcare systems will need to adapt to ensure these therapies are complemented by lifestyle interventions and regular patient engagement to maximize their benefits.
